The primary objective of the study is to describe the real-life conditions of use and exposure of cabozantinib in France in two cohorts defined by their treatment initiation period.
Study Type
OBSERVATIONAL
Enrollment
450
Ipsen Central Contact
Paris, France
Duration of treatment exposure
Time frame: during the whole study period for a maximum of 28 to 31 months
Dose prescribed at initiation
Time frame: during the whole study period for a maximum of 28 to 31 months
Average Daily Dose
average daily dose received by subject during the treatment exposure
Time frame: during the whole study period for a maximum of 28 to 31 months
Number of subjects with ≥1 temporary interruptions
Time frame: during the whole study period for a maximum of 28 to 31 months
Number of interruptions per subject
Time frame: during the whole study period for a maximum of 28 to 31 months
Number of subjects with ≥1 dose modification(s)
Time frame: during the whole study period for a maximum of 28 to 31 months
Number of subjects with permanent discontinuations
Time frame: during the whole study period for a maximum of 28 to 31 months
Overall survival of subjects since cabozantinib initiation
Time frame: during the whole study period for a maximum of 28 to 31 months
Overall survival of subjects since RCC diagnosis.
Time frame: during the whole study period for a maximum of 28 to 31 months
Overall survival of subjects since metastatic diagnosis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: during the whole study period for a maximum of 28 to 31 months